GeneIII

Nanjing, China Founded: 2021 • Age: 5 yrs
GeneIII was founded in 2021 in Nanjing, China.

About GeneIII

GeneIII is a Healthcare company based in Nanjing (China) founded in 2021. GeneIII was founded in 2021 in Nanjing, China. GeneIII has raised $13.76 million across 1 funding round from investors including JAFCO Asia. GeneIII offers products and services including Ergothioneine (EGT) and Skincare and Supplement Applications. Its focus areas include Cosmeceuticals. Its legal entity in India is ζ±Ÿθ‹δ»…δΈ‰η”Ÿη‰©η§‘ζŠ€ζœ‰ι™ε…¬εΈ (U99999MH1977PLC010754).

Company details

GeneIII was established in 2021 and is located in Nanjing, China. The company operates within the biotechnology sector, as indicated by its name and domain geneiii.com.cn. Operations are based in China, with a focus on genetic-related activities inferred from the branding. Specific services and detailed business scope are not outlined in available data, positioning it as an emerging entity in the regional biotech landscape.

Key Metrics
  • Total Equity Funding
    $13.76M (USD)

    in 1 rounds

  • Latest Funding Round
    $13.76M (USD), Seed

    Apr 2025

  • Investors

Products & Services of GeneIII

GeneIII offers a comprehensive portfolio of products and services, including Ergothioneine (EGT) and Skincare and Supplement Applications.

Ergothioneine (EGT)
Bioactive Raw Materials

Ergothioneine is produced as an antioxidant raw material for health and beauty applications

Skincare and Supplement Applications
Health Products

Applications of Ergothioneine are supplied for oral capsules and skincare formulations

Funding Insights of GeneIII

GeneIII has successfully raised a total of $13.76M through 1 strategic funding round. The most recent funding activity was a Seed round of $13.76 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $13.76M
  • Total Rounds 1
  • Last Round Seed β€” $13.76M
  • First Round $13.76M

    (Apr 2025)

  • Investors Count 1

All 1 funding rounds of GeneIII with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2025$13.76MSeed–JAFCO Asia
–
Valuation history

1 investors in total: 1 institutional.

Investors in GeneIII

GeneIII has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include JAFCO Asia.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Investments in early-stage tech startups are made by JAFCO Asia.
jafcoasia.comSingapore, Singapore
Premium access

Investor details for GeneIII

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of GeneIII

2 dated milestones of GeneIII across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded GeneIII is founded.
  2. Funding First funding round of $13.8M.

Web traffic of GeneIII

The website of GeneIII (geneiii.com.cn) receives about 4.6K visits a month.

  • Monthly visits
    4.6K
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Geneiii

Premium access

Complete news archive for GeneIII

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GeneIII

GeneIII was founded in 2021 and raised its 1st funding round 4 years after it was founded.

GeneIII is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.

GeneIII is a funded company, having raised a total of $13.76M across 1 funding round to date. The company's 1st funding round was a Seed of $13.76M, raised on Apr 2025.

GeneIII was established in 2021 and is located in Nanjing, China. The company operates within the biotechnology sector, as indicated by its name and domain geneiii.com.cn. Operations are based in China, with a focus on genetic-related activities inferred from the branding. Specific services and detailed business scope are not outlined in available data, positioning it as an emerging entity in the regional biotech landscape.

GeneIII offers Ergothioneine (EGT) and Skincare and Supplement Applications.

GeneIII has 1 investor. Key investors include JAFCO Asia.

GeneIII operates through ,.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available